Cosalane compounds and methods for their use

Details Cosalane compounds and methods for their use Cosalane compounds and methods for their use

2001-01-29

2003-05-13

Qazi, Sabiha (Department: 1616)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S169000, C514S182000, C514S171000, C552S505000, C552S522000, C552S525000, C552S540000

Reexamination Certificate

active

06562805

ABSTRACT:

BACKGROUND OF THE INVENTION
The present invention relates generally to methods, compounds and compositions for inhibiting effective binding of a chemokine to its cellular receptor. The compounds and compositions include cosalane and analogs thereof. The invention further relates to methods, compounds and compositions for treating inflammatory diseases.
Inflammation is a natural immune system response to injury or destruction of tissues and serves to destroy or otherwise confine an injurious agent or injured tissue. The inflammatory process includes targeting immune system and other cells to the site of damage to effect repairs. Although the response is generally protective in nature, in many cases it results in various disease states. A variety of molecules are involved in the inflammation process, including chemokines.
Chemokines are 8-15 Kda secreted chemoattractant proteins that are released by cells at a site of tissue injury and are regarded as important mediators of inflammation due to their ability to enhance migration of certain immune system cells, including, for example, T-cells, B-cells, basophils, neutrophils, and macrophages. Chemokines have been shown to induce directional leukocyte migration (chemotaxis) by binding to seven transmembrane G-coupled protein receptors (8). Chemokines also function to induce other inflammation-related events, including lysosomal enzyme release, respiratory burst, and histamine release. The chemokines and their receptors have been shown to participate in several disease states including allergy and asthma, (9,10) and angiogenesis during solid-tumor development (11). Inhibiting many of these undesired chemokine-induced processes may be beneficial in treating many inflammatory diseases. Compounds, compositions and methods of inhibiting chemokine-induced processes are thus needed. The present invention addresses this need.
SUMMARY OF THE INVENTION
It has been discovered that cosalane and analogs thereof are effective at inhibiting effective binding of a chemokine to its cellular receptor. Accordingly, the present invention provides methods for inhibiting such interactions and compounds and compositions effective for such inhibition.
In one aspect of the present invention, methods of inhibiting binding of a chemokine to its cellular receptor are provided. In one form, a method includes contacting a cellular population with an effective amount of cosalane or an analog thereof as described herein.
In a second aspect of the invention, methods of treating an inflammatory disease are also provided. In one form, a method includes administering to a patient a therapeutically effective amount of cosalane or an analog thereof as described herein. Compositions that include cosalane or analog thereof in combination with an active agent are further provided.
In a third aspect of the present invention, compounds effective in the methods described herein are provided. The compounds include cosalane analogs as described herein.
It is an object of the invention to provide methods and compounds for inhibiting effective binding of a chemokine to its cellular receptor, so that inflammatory or other processes initiated by the chemokines will be inhibited.
It is a further object of the invention to provide methods and compounds for treating an inflammatory disease.
These and other objects and advantages of the present invention will be apparent from the descriptions herein.


REFERENCES:
patent: 5439899 (1995-08-01), Cushman et al.
Johnston et al., International J. of Pharmaceutics (2002), 231(4), 197-211.*
Santosh et al., J. Med. Chem., (2001), 44, 703-714.*
Venkatesh et al., Pharmaceutical Research, (1996), vol. 13, No. 10, 1453-1459.*
Howard, O.M.J. et al.,Inhibition of RANTES/CCRI-Mediated Chemotaxis by Cosalane and Related Compounds,Biorg. Med. Chem. Lett. 11:59-62 (2001).
Santhosh, K.C. et al.,Anti-HIV Activity of a Series of Cosalane Amino Acid Conjugates,Bioorganic & Med. Chem. Lett. 10:2505-2508 (2000).
Paul, G.C. et al.,Identification of Optimal Anion Spacing for Anti-HIV Activity in a Series of Cosalane Tetracarboxylates,Bioorganic & Med. Chem. Lett., 10:2149-2152 (2000).
Casimiro-Garcia, A. et al.,Synthesis and Anti-HIV Activity of Cosalane Analogues Incorporating Nitrogen in the Linker Chain,Bioorganic & Med. Chem., 8:191-200 (2000).
Ruell, J.A. et al.,Synthesis and Anti-HIV Activity of Cosalane Analogues with Substituted Benzoic Acid Rings Attached to the Pharmacophore through Methylene and Amide Linkers,J. Org. Chem. 64:5858-5866 (1999).
Cushman, M. et al.,Extension of the Polyanionic Cosalane Pharmacophore as a Strategy for Increasing Anti-HIV Potency,J. Med. Chem. 42:1767-1777 (1999).
Cushman, M. et al.,Synthesis of a Cosalane Analog with an Extended Polyanionic Pharmacophore Conferring Enhanced Potency as an Anti-HIV Agent,Bioorganic & Med. Chem. Lett. 8:833-836 (1998).
Keyes, R.F. et al.,Correlation of Anti-HIV Potency with Lipophilicity in a Series of Cosalane Analogs Having Normal Alkenyl and Phosphodiester Chains as Cholestane Replacements,J. Med. Chem. 39:508-514 (1996).
Keyes, R.F. et al.,Studies Directed Toward a More Potent Cosalane Pharmacophore: Synthesis of a Substituted Tetraphenylethylene Which Inhibits the Cytopathic Effect of HIV-1,Med. Chem. Res. 372-376 (1996).
Golebiewski, W.M. et al.,Exploration of the Effects of Linker Chain Modifications on Anti-HIV Activities in a Series of Cosalane Analogues,Bioorganic & Med. Chem. vol. 4, No. 10:1637-1648 (1996).
Cushman, M. et al.,Cosalane Analogues with Enhanced Potencies as Inhibitors of HIV-1 Ptotease and Integrase,J. Med. Chem. 38:443-452 (1995).
Cushman, M. et al.,Design Synthesis, and Biological Evaluation of Cosalane, a Novel Anti-HIV Agent which Inhibits Multiple Features of Virus Reproduction;J. Med. Chem. 37:3040-3050 (1994).
Golebiewski, W.M. et al.,Design and Synthesis of Cosalane, a Novel Anti-HIV Agent,Bioorganic & Med. Chem. Lett. vol. 3, vol. 3, No. 8:1729-1742 (1993).

Affiliated with

Also associated with

Rating

Cosalane compounds and methods for their use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cosalane compounds and methods for their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cosalane compounds and methods for their use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3084977